Hologic’s stock soars after revenue outlook raised well above analyst expectations

Shares of Hologic Inc. shot up 10% in premarket trading Friday, after the diagnostics products and medical imaging systems company raised its fiscal fourth-quarter revenue outlook, to put it well above analyst expectations, citing increased production and strong sales of COVID-19 tests. With more than 80% of its fourth-quarter complete, the company said it now expects revenue to rise 54% to 60% from a year ago to $1.225 billion to $1.275 billion, up from previous guidance of $925 million to $1.025 billion. The FactSet consensus was $986.5 million. Other reasons for the increased outlook include strong sales of its Panther instruments and “slightly” better-than-expected performances in its breast and skeletal business and its surgical division. The stock has rallied 18.8% over the past three months through Thursday, while the S&P 500 has gained 11.2%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Read Full Story

Latest posts by Market Watch (see all)

Be the first to comment

Leave a Reply

Your email address will not be published.


*